Oncogene licenses cancer detection technology to Bayer for inclusion on Technicon Immuno 1 analyzer.
This article was originally published in The Gray Sheet
Executive Summary
ONCOGENE SCIENCE CANCER DIAGNOSTIC R&D DEAL WITH BAYER provides a fully automated serum-based analyzer, Bayer's Technicon Immuno 1, for Oncogene's in vitro cancer detection technology. The deal replaces a development pact with Becton Dickinson that had been in place since 1984. In September, Oncogene chose not to renew the deal with BD because the firm does not offer an automated immunoassay system.
You may also be interested in...
Bayer's $11 Mil. Oncogene Purchase Adds Oncology Diagnostics Stable
Bayer's acquisition of OSI Pharmaceuticals' diagnostic business builds on the firms' collaborative efforts to run OSI's HER-2/neu breast cancer assay on Bayer's Technicon Immuno I automated immunoassay.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.